- Novocure ( NASDAQ: NVCR ) is down ~15% in Monday afternoon trading after releasing preliminary Q4 2022 figures that came in below estimates.
- The oncology focused pharma is expecting Q4 net revenue of $128.4 million, below the consensus in $128.69M.
- As of December 31, 2022, there were 3,430 active patients on Optune, the Swiss pharma's Tumor Treating fields therapy for glioblastoma. Bloomberg had estimated 3,499.
- Seeking Alpha contributor BioSci Capital Partners on Monday reiterated its strong buy rating fopr Novocure ( NVCR ) saying upcoming catalysts could lead to more upside .
For further details see:
Novocure off 15% on preliminary Q4 results